The path from an initial scientific hypothesis to an approved drug remains long, risky, and costly. Modern estimates put the average timeline for developing a new drug at 12–13 years, with only 1–2 of every 10,000 screened compounds eventually reaching the market. Discovery and pre-clinical development alone can take 4–7 years, while clinical phases may last another 8–10 years. Costs are equally substantial, with recent figures ranging from $2.5–3 billion per approved drug (DiMasi et al., 2016).

Attrition remains the greatest challenge. Only ~60–70% of compounds advance beyond Phase I trials, ~30–35% of Phase II candidates succeed, and the overall probability of approval from first-in-human studies is just 10–15%. Despite significant advances in computational biology, machine learning, and high-throughput screening (HTS), the failure rate highlights the difficulty of balancing efficacy, safety, and drug-like properties.

This article provides a comprehensive overview of the drug discovery workflow, structured around traditional stages but expanded to highlight assay development, emerging technologies, and future trends. Medicinal chemistry and pharmacology remain at the core, but their integration with AI, DNA-encoded library drug discovery, and precision medicine is reshaping timelines and strategies.

Target identification is the first and most critical step in drug discovery. This phase involves selecting a biological molecule, usually a protein, that plays a significant role in disease. The ideal target should be directly implicated in disease pathogenesis, druggable, and capable of being modulated to produce a therapeutic effect without adverse effects (Overington et al., 2006).

• Genomic and Transcriptomic Technologies: Genome-wide association studies (GWAS) and RNA sequencing uncover genes or pathways associated with disease, providing insights into genetic mechanisms (Visscher et al., 2017).
• Proteomics: Mass spectrometry–based proteomics identifies proteins altered in disease states, helping uncover new molecular targets (Aebersold & Mann, 2016).
• Phenotypic Screening: Screening compounds in cellular or animal models allows identification of active molecules first, followed by linking to underlying targets (Vincent et al., 2022).

The challenge in this stage lies in ensuring the target is both druggable and selectively modulated by small molecules or biologics, which is essential for therapeutic viability.

Once a potential target has been identified, the next step is to validate its role in disease. This phase confirms that modulating the target yields therapeutic benefit.

• Genetic Validation: Tools such as CRISPR/Cas9 and RNA interference (RNAi) allow precise knockouts or knockdowns of candidate genes, providing direct evidence of disease involvement (Moore, 2015).
• Pharmacological Validation: Chemical probes, biologics, or small molecules are used to modulate target activity. Demonstrating efficacy in preclinical models strengthens confidence in the target (Swinney & Anthony, 2011).

Validated targets should demonstrate clear disease association, a defined mechanism of action, and the potential for selective pharmacological intervention without off-target effects (Emmerich et al., 2021).

Following validation, researchers seek compounds that modulate the target. This stage often employs high-throughput screening (HTS), where large chemical libraries (10⁴–10⁶ compounds) are tested in automated assays. While hit rates are typically low, identifying even a few promising molecules provides starting points (Macarron et al., 2011).

• Fragment-Based Drug Discovery (FBDD): Screens small fragments that bind weakly to targets but can be optimized iteratively into potent compounds (Bon et al., 2022).
• Virtual Screening: Computational docking and machine learning models predict binding affinity, narrowing candidates for experimental testing (Lyu et al., 2023).
• DNA-Encoded Library (DEL) Technology: Each compound is tagged with a DNA barcode encoding its structure. DEL enables screening of up to 10¹² molecules in a single tube, requiring minimal protein and time. This approach has become central to DNA-encoded library drug discovery (Satz et al., 2022)

Before large-scale screening or optimization, assay development ensures that biological activity and toxicity can be reliably measured. Robust assays improve hit quality and reduce false positives.

• Types of Assays: Include biochemical assays (enzyme activity), cell-based assays (signal transduction), and phenotypic assays (functional outcomes).
• Key Considerations: Sensitivity, reproducibility, scalability, and physiological relevance.
• Impact on Hit Quality: Assay selection influences which hits are identified. For example, highly artificial assays may capture binders with no therapeutic potential, while physiologically relevant assays enrich for clinically translatable molecules.

According to Danaher Life Sciences, assay development is increasingly critical as drug discovery integrates HTS, DELs, and phenotypic screening.

The hit-to-lead (H2L) stage focuses on refining hits into more potent, selective, and drug-like molecules.

• tructure–Activity Relationship (SAR) Studies: Synthesize analogs to explore how chemical modifications affect activity.
• Early ADME/Toxicity Profiling: Screen candidates for solubility, permeability, metabolic stability, and cytotoxicity.
• Optimization for Drug-Like Properties: Modify compounds to improve bioavailability, minimize off-target interactions, and enhance selectivity (Campbell et al., 2018)

Vipergen highlights how DEL hit identification can be paired with rational H2L optimization, accelerating time-to-lead compared with traditional HTS approaches.

Lead optimization further refines molecules for potency, safety, and pharmacokinetics.

Key Aspects

• Stereochemistry: Enantiomeric differences can significantly impact potency or toxicity.
• Scaffold Hopping: Replacing core molecular scaffolds while retaining binding to improve solubility or reduce off-target effects (Hu et al., 2017).
• Pharmacokinetic Optimization: Adjust lipophilicity, design prodrugs, or shield metabolic hot spots to enhance bioavailability and reduce clearance (Ballard et al., 2013).

At this stage, medicinal chemistry and pharmacology converge to deliver candidates suitable for preclinical development.

Before human trials, candidates undergo extensive testing in vitro and in vivo. This stage typically lasts 3–6 years.

Components

• Toxicology Studies: Evaluate acute/chronic toxicity, carcinogenicity, genotoxicity, and reproductive effects.
• Pharmacokinetic Studies: Assess ADME properties to confirm expected behavior in animals.
• Formulation Development: Optimize delivery, stability, and bioavailability.

If successful, researchers submit an Investigational New Drug (IND) application to agencies such as the FDA or EMA. Approval is required before clinical trials can begin.

Clinical development remains the most resource-intensive phase, often spanning 8–10 years. Trials progress through three major phases:

Phase I

• Participants: 20–100 healthy volunteers.
• Focus: Safety, dosage, pharmacokinetics.
• Success Rate: ~60–70% advance to Phase II.

Phase II

• Participants: 100–500 patients with the target disease.
• Focus: Efficacy, dose ranging, short-term safety.
• Success Rate: ~30–35% advance to Phase III.

Phase III

• Participants: Thousands of patients across multiple sites.
• Focus: Confirm efficacy, monitor long-term safety.
• Success Rate: ~50–60% achieve endpoints and support regulatory submission.

If Phase III is successful, a New Drug Application (NDA) is filed with regulators (FDA, EMA) for approval.

AI/ML lowers costs, shortens development time, and improves predictive accuracy. Applications include:

• Target Identification: Mining omics datasets for druggable targets.
• Virtual Screening: Rapidly evaluating millions of compounds.

ADME/Toxicity Prediction: Modeling safety liabilities before costly in vivo work.
Challenges remain in data quality, model interpretability, and integration into regulatory workflows.

Traditional HTS can test up to 10⁶ compounds but is expensive. In contrast, DEL screening covers up to 10¹² molecules per experiment, requiring nanogram protein amounts and minimal assay time. Innovations such as in-cell DEL and Vipergen’s YoctoReactor® platform enhance physiological relevance and synthetic diversity.

CRISPR enables precise genome engineering for target validation and disease modelling. Knockout cell lines and engineered disease models reduce uncertainty about whether target modulation translates to therapeutic benefit (Cytosurge on CRISPR applications).

Precision Medicine, Generative AI, and Regulatory Acceleration

• Precision Medicine: Stratifies patients based on genetics/biomarkers to tailor therapies (Danaher Life Sciences).
• Generative AI: Accelerates molecular design, especially when powered by GPU-accelerated computing.

Regulatory Innovation: Pathways like priority review, conditional approval, and orphan drug designations shorten timelines for high-need therapies.

The drug discovery process is a complex, interdisciplinary journey requiring sustained collaboration between biology, chemistry, and pharmacology. While the path from target identification to clinical approval remains long—12–13 years on average—emerging technologies are beginning to reshape success rates and timelines.

Artificial intelligence, DNA-encoded library drug discovery, and CRISPR gene editing offer powerful ways to accelerate early discovery and reduce risk. Trends such as precision medicine, generative AI, and regulatory acceleration further signal a shift toward more efficient and personalized development.

Companies like Vipergen are at the forefront of these innovations, offering proprietary DEL platforms that open new chemical space and improve hit discovery efficiency. As these tools mature, the industry can expect shorter timelines, lower attrition rates, and more effective therapies for patients worldwide.

• Aebersold, R., & Mann, M. (2016). Mass-spectrometric exploration of proteome structure and function. Nature, 537(7620), 347–355.
• Ballard, P., et al. “Metabolism and Pharmacokinetic Optimization Strategies in Drug Discovery.” Drug Discovery and Development, edited by R. G. Hill and H. P. Rang, 2nd ed., Churchill Livingstone, 2013, pp. 135–155. ScienceDirect. 
• Bon, M., et al. (2022). Fragment-based drug discovery-the importance of high-quality molecule libraries. Mol Oncol. 16(21), 3761-3777.
• Campbell,I. B., et al. (2018). Medicinal chemistry in drug discovery in big pharma: past, present and future. Drug Discovery Today, 23(2), 219-234.
• DiMasi, J. A., et al. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20–33.
• Emmerich, C.H., et al (2021). Improving target assessment in biomedical research: the GOT-IT recommendations. Nature Reviews Drug Discovery, 20, 64–81.
• FDA (2020). Investigational New Drug (IND) Application. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov.
• Hu, Y., et al, (2017). Recent Advances in Scaffold Hopping. Journal of Medicinal Chemistry, 60(4), 1238-1246.
• Lyu, J., et al. (2023) Modeling the expansion of virtual screening libraries. Nat Chem Biol, 19, 712–718.
• Macarron, R., et al. (2011). Impact of high-throughput screening in biomedical research. Nature Reviews Drug Discovery 10, 188–195.
• Moore, J., (2015). The impact of CRISPR–Cas9 on target identification and validation. Drug discovery today, 20(4), 450-457.
• Overington, J. P., et al. (2006). How Many Drug Targets Are There? Nature Reviews Drug Discovery, 5(12), 993–996.
• Satz, A.L., et al. (2022) DNA-encoded chemical libraries. Nat Rev Methods Primers 2(3), 1-17. 
• Swinney, D. C., & Anthony, J. (2011). How were new medicines discovered? Nature Reviews Drug Discovery, 10(7), 507–519.
• Vincent, F. et al. (2022). Phenotypic drug discovery: recent successes, lessons learned and new directions. Nature Reviews Drug Discovery 21, 899–914.
• Visscher, P. M., et al. (2017). 10 years of GWAS discovery: Biology, function, and translation. American Journal of Human Genetics, 101(1), 5–22.

Do you have an inquiry?

Get In Touch

Drug discovery is a search problem at massive scale: biology is complex, chemical space is enormous, and timelines are unforgiving. The challenge isn’t just finding active compounds — it’s finding reproducible, mechanism-relevant starting points fast enough to justify the next wave of chemistry and biology.

High-throughput screening (HTS) is the workhorse approach for that early decision-making. In drug discovery high-throughput screening, automated platforms test hundreds of thousands to millions of compounds against a biological target or cellular phenotype to identify “hits” worth follow-up. By combining miniaturized assays in microplates with robotics, sensitive detection, and data analytics, HTS compresses months of manual work into days to weeks and generates quantitative starting points for hit-to-lead optimization.

Why HTS matters: HTS enables standardized experimentation at scale — so teams can triage chemical matter earlier, reduce downstream attrition, and focus resources on the most promising chemotypes.

High-throughput screening (HTS) is a systematic, automation-driven method for identifying biologically active compounds by testing very large libraries against a target (e.g., an enzyme or receptor) or a cellular phenotype. The primary goal is hit discovery: finding reproducible chemical starting points that can be optimized into leads through medicinal chemistry and iterative biology.

HTS is widely used across pharmaceutical and biotech R&D, CROs, and academic screening centers to prioritize the most promising candidates early—especially when the mechanism is well-defined (target-based screening) or when a phenotype provides the best disease-relevant readout (phenotypic screening).

In practice, HTS miniaturizes assays into microplates and uses robotics for dispensing, incubation, and detection. Software then normalizes results, applies quality-control statistics (e.g., Z′), and flags “hits” for confirmation, orthogonal testing, and early structure–activity relationship (SAR) learning.

Related technologies: DNA-Encoded Library Screening 

Since the emergence of HTS in the early 1990s, the screening collections have grown from 50-100,000 compounds to several million today (TheScientist 2024). Screening compound collections of this size is challenging, and efficient automation and organization are essential for successful HTS campaigns. 

The integration of robotics, miniaturization, and powerful data analytics tools has made HTS a staple in pharmaceutical research and development (R&D), particularly among organizations aiming to achieve high-efficiency lead generation while minimizing resource expenditure. 

A typical HTS campaign, from target validation to hit confirmation, can take anywhere from several weeks to a few months, depending on the complexity of the assay, the size of the compound library, and the level of automation employed. In well-established platforms, timelines as short as 4–6 weeks from assay readiness to hit confirmation are possible.

Figure 1: Overview of the HTS workflow

Compound libraries provide the chemical diversity to discover new starting points. Targets define what “activity” means biologically. Assays translate biology into a measurable signal, and hit identification/validation separates true actives from artifacts using confirmation, orthogonal methods, and early SAR.

1) Target selection and validation

Targets are chosen based on disease relevance, druggability, and feasibility of building a robust assay. Validation typically combines genetic/clinical evidence, pathway context, and tool molecules or reference ligands to confirm that modulating the target produces a meaningful biological effect.

2) Assay development and optimization

Assay design defines the readout (biochemical vs. cell-based, endpoint vs. kinetic) and the detection modality (e.g., fluorescence, luminescence). Optimization focuses on robustness and scalability: selecting controls, confirming DMSO tolerance, minimizing edge effects, and tuning conditions to achieve strong signal windows. Screening teams commonly track assay performance with metrics like Z′-factor, signal-to-background, and coefficient of variation. Z′-factor is a standard robustness metric in HTS; values closer to 1 indicate better separation between positive and negative controls (often ≥0.5 is considered excellent for screening, Zhang 1999).

3) Compound library selection and management

Libraries may be diverse (“discovery”) or target-focused (e.g., kinase sets, covalent fragments, CNS subsets). Practical success depends on logistics: compound identity/purity verification, solubility and stability in DMSO, barcoding/plate maps, storage conditions, and “cherry-pick” traceability for follow-up testing.

4) Plate setup and compound dispensing

Compounds are formatted into assay-ready plates (often 384- or 1536-well) using acoustic dispensing, pin tools, or automated pipetting. Plate design includes controls, replicates, and sometimes concentration series. Sealing, humidity control, and standardized timing reduce evaporation-driven artifacts.

5) Primary screen execution

Automation coordinates dispensing, incubation, and readout across thousands of wells with minimal human intervention. Environmental consistency (temperature, CO₂ for cells, incubation times) and batch monitoring are critical to reduce drift and improve reproducibility.

6) Data acquisition and processing

Detection instruments generate raw signals that are normalized to controls, quality-checked, and transformed into activity scores. Pipelines flag outliers, compute plate QC, and apply hit-calling thresholds (often followed by curve fitting when concentration-response data are available).

7) Hit confirmation and prioritization

Putative hits are retested (often from fresh material) to confirm reproducibility, followed by dose–response curves to estimate potency. Orthogonal assays and counterscreens help eliminate detection interference, aggregation, and non-specific toxicity. Confirmed hits are prioritized using early SAR, selectivity profiling, and preliminary developability checks (e.g., solubility, stability, basic ADME flags). Because primary-screen hit rates are often well under 1% (and sometimes far lower), confirmation and orthogonal validation are essential to avoid chasing artifacts.

Figure 2: Flowchart of the high-throughput screening (HTS) workflow: target selection and validation → assay development and optimization → compound library selection and management → plate setup and compound dispensing → automated primary screening → data processing and hit calling → hit confirmation and validation, with iteration back to assay optimization.

HTS platforms combine miniaturized assay formats with automation and high-sensitivity detection. While exact setups vary by assay type, most screening centers rely on the same core technology stack:

Modern HTS typically uses 96-, 384- and 1536-well plates (with specialized formats for ultra-miniaturization). Smaller volumes reduce reagent cost per data point and increase throughput, but demand tighter control of evaporation, mixing, and timing.

Automation starts with accurate dosing: tip-based liquid handlers, bulk dispensers for reagents, and low-volume tools (e.g., acoustic dispensing or pin tools) for transferring compounds. These systems standardize timing and reduce variability compared to manual pipetting.

Readout choice determines which instrument you need and what artifacts to watch for. Common modes include:

• • Fluorescence intensity (FI): sensitive, widely used for binding and enzymatic assays.
  • Luminescence (LUM): high sensitivity with low background (often luciferase-based).
  • Absorbance (ABS): straightforward optical density measurements for many enzyme reactions.
  • FRET / TR-FRET: proximity-based fluorescence; TR-FRET reduces background by time-gating.
  • BRET: proximity readout driven by bioluminescence rather than excitation light.
  • AlphaScreen/AlphaLISA: bead-based proximity assays that work well for difficult targets.

Integrated systems may include robotic arms, plate stackers/carousels, incubators (temperature/CO₂/humidity), sealers/peelers, and scheduling software to run assays consistently—often around the clock.

High-content screening (HCS) is often considered a subset/adjacent approach to HTS: instead of a single signal per well, HCS uses automated microscopy and image analysis to quantify multi-parameter cellular phenotypes (e.g., morphology, localization, pathway markers). HCS is especially valuable for complex biology, but typically increases data volume and analysis complexity.

HTS vs. HCS (high-content screening): HTS and HCS share automation and microplate workflows, but they differ in readout complexity and analysis burden.

Because HTS produces large, plate-structured datasets, informatics is not optional. LIMS/ELN tools track sample provenance, plate maps, concentrations, and QC metrics across runs. Analytics pipelines handle normalization, curve fitting, outlier detection, hit calling, and reporting—enabling faster triage and more reproducible decision-making.

The success of an HTS campaign depends as much on the library as the assay. Libraries can be built in-house or sourced commercially, and are typically curated to balance chemical diversity, developability, and screening robustness.

Libraries are either generated by in-house laboratories or by purchasing commercially available compound collections. A high-quality chemical library will have the following features:

• Chemical diversity & coverage: Broad scaffold and shape diversity (including 3D-rich/ sp³ content) to maximize novel chemotypes while maintaining clusters of close analogs for rapid SAR.
• Drug-like property profile: Filtered for desirable ranges (e.g., MW, clogP, HBD/HBA, TPSA) tailored to the target class; include subsets (fragment-, lead-, and probe-like).
• Quality & identity control: Verified purity/identity (LC-MS/NMR), low salts/residual reagents, and robust metadata (SMILES, stereochemistry, batch history).
• Liability filtering: Removal of PAINS, frequent hitters, redox cyclers, covalent/reactive moieties (unless intentional), chelators, and aggregators; include counterscreen flags.
• Solubility & stability: DMSO compatibility, precipitation checks, controlled water content, and policies to minimize freeze–thaw cycles; stability monitoring over time.
• IP and novelty: Preference for synthetically accessible, novel scaffolds with freedom-to-operate and avenues for follow-up chemistry.
• Biology-aware subsets: Target-class or modality-enriched panels (kinase-focused, PPI, CNS-penetrant, covalent warheads) to boost hit relevance.
• Automation-ready formatting: Standardized plate formats (384/1536), barcoding, tracked concentrations/volumes, and plate maps with control wells.
• Data & logistics: LIMS integration, cherry-pickability, replenishment strategies, and provenance auditing—crucial for reproducibility and scale.

Library synthesis and evolution: Many modern HTS collections are built using combinatorial and diversity-oriented synthesis to generate broad scaffold coverage at scale. Key challenges include maintaining purity and identity across thousands of compounds, increasing 3D/sp³-rich diversity (to avoid overly “flat” chemical space), and ensuring compounds remain soluble and stable during storage and repeated handling. As a result, many organizations pair experimental curation with computational design to target underrepresented regions of chemical space while preserving tractable follow-up chemistry.

Despite the scalability of this method, there are significant challenges:

• Achieving High Purity: With automated synthesis and scale, maintaining consistent purity across thousands of compounds is difficult. Impurities can interfere with assay results and lead to false positives or negatives.
• 3D Diversity and Stereochemistry: Traditional combinatorial libraries often result in flat, aromatic-rich compounds. There is a growing emphasis on incorporating 3D structural diversity to better mimic natural ligands, improve bioavailability, and reduce attrition rates.
• Novel Scaffolds: Generating libraries with novel scaffolds, rather than just variations on known drugs, remains a key challenge to unlock unexplored chemical space.
• Cost and Logistics: Synthesizing, validating, storing, and reformatting HTS libraries for screening can be costly and logistically intensive, especially for startups with limited infrastructure.

To address these issues, some companies are turning to diversity-oriented synthesis (DOS) and leveraging AI-driven library design tools to predict and prioritize structurally and functionally rich chemical spaces.

HTS contributes across multiple phases of discovery — from confirming target biology to generating and refining lead series. In practice, teams use HTS screening differently depending on where they are in the pipeline:

1) Target identification and validation

HTS can support target validation by testing tool compounds, reference ligands, or focused libraries to confirm that modulating a target produces the expected biological effect. In phenotypic settings, screening can also help connect pathway perturbations to actionable targets through follow-up deconvolution.

2) Lead discovery and hit identification

This is HTS’s primary role: running large-scale small molecule screening to identify initial “hits” from diverse or target-focused libraries, followed by confirmation and orthogonal assays to remove artifacts.

3) Lead optimization and SAR development

After hits are confirmed, iterative screening of close analogs (often in dose–response format) accelerates structure–activity relationship (SAR) learning. Secondary and counterscreen panels are used to improve potency, selectivity, and developability while reducing false-positive mechanisms.

HTS is used in a wide range of discovery applications, including:

• Hit identification: Primary screens reveal active compounds against a biological target.
• Lead optimization: Iterative screening of compound analogs refines efficacy, potency, and ADMET properties.
• Target deconvolution: In phenotypic screens, HTS helps elucidate the mechanism of action of active compounds.
• Mechanistic studies and pathway profiling: HTS enables systematic study of compound effects on signaling pathways or gene expression.
• Functional genomics: Identifying genes that play roles in specific pathways and understanding gene functions. 
• Toxicology: Identifying potential toxicity of entire compound libraries.

HTS provides a competitive advantage by enabling rapid hypothesis testing, reducing time-to-discovery, and enhancing the quality of candidate selection. By leveraging public HTS data repositories like PubChem BioAssay, smaller firms can also validate in-house findings or expand SAR understanding.

A classic HTS success is ivacaftor (VX-770) for cystic fibrosis. Vertex screened ~228,000 small molecules in a cell-based fluorescence assay to find CFTR “potentiators,” then optimized hits into VX-770, which increased CFTR channel open probability and restored chloride transport in vitro. Clinical studies confirmed benefit for patients with gating mutations (e.g., G551D), leading to the first CFTR-modulator approval in 2012. This path—from HTS hit to approved precision therapy—is documented in primary papers and regulatory/web sources (Van Goor 2009, Vertex 2012).

When assays are well-optimized and libraries are well-curated, HTS offers several practical advantages in early discovery:

• Speed and efficiency: rapidly tests large libraries to identify starting points earlier in the pipeline.
• Lower cost per data point: miniaturization and automation reduce reagent use and per-well labor.
• Access to novel chemical starting points: diverse libraries increase the chance of finding new chemotypes.
• Reduced manual labor and improved reproducibility: standardized automation reduces human error and variability.

Better prioritization under uncertainty: quantitative screening + early SAR improves decision-making before expensive in vivo work.

HTS trades depth-per-experiment for breadth and standardization. The most common pitfalls fall into assay artifacts, data complexity, operational cost, and library representativeness—so successful campaigns plan for triage and validation from day one.

A single campaign can generate millions of datapoints across plates, replicates, timepoints, and conditions—especially when imaging or multi-parameter readouts are used. Without standardized normalization, plate/QC monitoring, and reproducible pipelines for hit calling and curve fitting, teams can either miss real actives (over-filtering) or chase noise (under-filtering). This is why HTS groups invest heavily in informatics, statistical QC, and clear triage criteria before screening begins.

HTS requires significant upfront investment in robotics, detection hardware, environmental control, and trained staff. Even when the per-well cost is low, the platform-level cost can be a barrier for smaller teams—driving interest in partnerships, CRO models, or complementary approaches like DEL or virtual screening.

Quality control (QC) safeguards the credibility of high-throughput screening data; without it, projects burn time and budget chasing artifacts. QC typically spans two buckets: plate-based and sample-based controls. Plate-based controls assess how each plate performs and flag assay problems—think pipetting mistakes or “edge effects” from evaporation at perimeter wells. Sample-based controls track variability in biological response or compound potency across runs. A common metric is the minimum significant ratio (MSR), which quantifies assay reproducibility and the degree to which control or sample potencies differ between experiments.

A persistent challenge in HTS is the presence of pan-assay interference compounds (PAINS). These are compounds that produce false positives across multiple assay types due to their chemical reactivity, aggregation, redox activity, or interference with assay detection mechanisms (Baell 2018). PAINS can skew screening results, misdirect follow-up efforts, and waste valuable resources.

Identifying and filtering out PAINS early in the screening process is crucial. Computational filters and curated substructure databases are used to flag known PAINS motifs. However, these tools are not foolproof, and careful experimental validation remains necessary. Companies must balance the risk of excluding potentially valuable compounds with the need to eliminate confounders that undermine screening fidelity.

Educating screening scientists and medicinal chemists about PAINS and investing in robust triaging strategies can dramatically improve hit quality and downstream success rates.

DEL technology allows the screening of billions of compounds by tagging each with a DNA barcode, enabling solution-phase binding assays and rapid hit identification. One of the major advantages of DEL is its significantly lower cost compared to HTS, both in terms of library acquisition and operational expenses. DEL libraries can be synthesized or accessed through partnerships at a fraction of the cost of traditional HTS libraries. Moreover, DEL screening is conducted in a single reaction tube, eliminating the need for hundreds or thousands of microtiter plates, complex automation, and high-throughput robotics. This makes the overall setup far simpler and more accessible for e.g. small biotech firms or early-stage discovery labs.

• Screens billions of DNA-barcoded compounds in solution-phase binding selections
• Lower cost per “virtual compound” compared with plate-based HTS
• Requires off-DNA resynthesis + follow-up functional assays to confirm activity
• Best for: fast binder discovery, very large chemical space exploration

FBDD involves screening low molecular weight compounds— “fragments”—that bind to a target with weak affinity but high specificity. Though individually less potent than typical HTS hits, these fragments serve as efficient starting points for lead optimization. Detection typically requires sensitive biophysical techniques such as NMR spectroscopy, surface plasmon resonance (SPR), or X-ray crystallography. A key advantage of FBDD is its efficiency: smaller libraries (often in the range of hundreds to a few thousand compounds) can yield highly novel chemical matter with desirable drug-like properties. 

As the complexity of therapeutic targets grows, the integration of high-throughput screening with multi-omics approaches (e.g., genomics, transcriptomics, proteomics, metabolomics) offers a more comprehensive understanding of drug-target interactions and downstream effects. By mapping screening hits to omics datasets, researchers can:

• Identify off-target activities or biomarkers associated with compound response
• Elucidate the mechanism of action with greater precision
• Predict efficacy across patient subtypes using systems biology models

Moreover, combining HTS results with transcriptomic or proteomic data can uncover pathway-level perturbations and reveal synergistic interactions in polypharmacology approaches. This integrative strategy not only supports more informed hit prioritization but also aligns with precision medicine objectives (Meissner 2022).

HTS is evolving beyond “faster plates” into smarter experimentation — combining automation, richer biology, and predictive analytics to reduce false positives, de-risk hits earlier, and prioritize chemistry that is more likely to translate.

AI is increasingly used to improve HTS decision-making at multiple points: identifying assay interferents, improving hit calling, prioritizing which hits to retest first, and predicting which chemotypes are most likely to survive follow-up validation. In more advanced workflows, active-learning loops can propose the next set of compounds to test, accelerating SAR development while reducing the number of experiments needed (Boldini 2024). 

Traditional HTS relies on 384–1536 well plates, but ultra-HTS pushes miniaturization into microfluidic droplets that act like tiny reaction vessels (often pico- to nanoliter volumes). These approaches can massively increase throughput and reduce reagent costs, while enabling single-cell or rare-event assays that are hard to run in plates (Yang 2025, Das 2025). 

More physiologically relevant models — including organoids, 3D cultures, and high-throughput organ-on-a-chip (OoC) systems — are being integrated into screening to improve translatability. These platforms aim to bridge the gap between simplified in vitro assays and in vivo outcomes by capturing tissue-level behavior (e.g., barrier function, flow, multicellular interactions) in scalable formats (Song 2024, Leung 2022). 

Label-free approaches reduce dependence on fluorescent or luminescent reporters and can provide more direct biochemical readouts. Two areas gaining momentum are:

• Biosensors (optical/electrochemical/piezoelectric) for real-time binding and kinetic measurements (Chieng 2024).
• Mass spectrometry–based screening (e.g., rapid injection or acoustic ejection MS) that can quantify substrates/products without labels and can reduce assay artifacts linked to reporters (Smith 2025, Winter, 2023).

Phenotypic screening is resurging as imaging, automation, and analysis improve. High-content screening (HCS) enables multi-parameter cellular profiling at scale, and modern image analysis (often ML-assisted) helps teams connect phenotypes to mechanisms and prioritize hits with stronger biological relevance (Seal 2024, Subramani 2024).

Quantum computing is still early for most discovery teams, but it may eventually impact drug discovery through faster molecular simulation and quantum machine learning approaches for high-dimensional prediction tasks. Near term, it is best viewed as an emerging capability rather than a standard HTS tool (Danishuddin 2025, Banait 2025). 

High-throughput screening remains one of the fastest ways to turn biological hypotheses into validated chemical starting points — especially when assay quality, library design, automation, and data triage are engineered as a single workflow. As HTS evolves toward AI-assisted analytics, ultra-miniaturization, label-free readouts, and more physiologically relevant models (3D systems and organ-on-a-chip), the winners will be the teams that can generate clean hits and learn reliable SAR quickly.

Vipergen supports discovery teams with scalable screening strategies utilizing the complementary approach of DNA-encoded library (DEL) screening, helping reduce uncertainty early and accelerate the path from target to lead. If you’re planning a screening campaign, consider aligning assay design, library strategy, and confirmation methods upfront to maximize signal quality and downstream success.

• Z′-factor (Z-prime): Assay quality metric based on signal window and variability; values closer to 1 indicate a more robust assay (often, ≥0.5 is considered excellent).
• IC50: Concentration of an inhibitor that reduces activity by 50%.
• EC50: Concentration of an activator/agonist that produces 50% of the maximal effect.
• SAR (Structure–Activity Relationship): Relationship between chemical structure changes and changes in biological activity.
• LIMS: Laboratory Information Management System for tracking samples, plates, results, and provenance.
• ELN: Electronic Laboratory Notebook for experimental records and workflows.
• FRET / TR-FRET: Proximity-based fluorescence readouts; TR-FRET uses time-resolved detection to reduce background.
• BRET: Proximity readout driven by bioluminescence rather than excitation light.
• PAINS: Pan-assay interference compounds that frequently cause false positives due to assay interference mechanisms.
• Orthogonal assay: A follow-up assay using a different readout to confirm true activity.
• Counterscreen: Assay designed to detect artifacts or off-target activity (e.g., reporter interference).
• ADMET: Absorption, distribution, metabolism, excretion, and toxicity.

• Baell, J. B., Nissink, J. W. M., 2018, Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017 – Utility and Limitations, ACS Chem. Biol., 13, 36-44. doi.org/10.1021/acschembio.7b00903
• Banait, A. S., et al., 2025, Advancing Drug Discovery and Material Science Using Quantum Simulations for Molecular Structures, Proceedings of the 6th International Conference on Information Management & Machine Intelligence, 43, 1-10. https://doi.org/10.1145/3745812.3745862 
• Blay. V. et al., 2020, High-Throughput Screening: today’s biochemical and cell-based approaches, Drug Discov. Today, 25, 10, 1807-1827. doi.org/10.1016/j.drudis.2020.07.024
• Boldini, D. et al., 2024, Machine Learning Assisted Hit Prioritization for High Throughput Screening in Drug Discovery, ACS Cent. Sci., 10, 4, 823-832. doi.org/10.1021/acscentsci.3c01517
• Chen, L. et al., 2016, mQC: A Heuristic Quality-Control Metric for High-Throughput Drug Combination Screening, Sci. Rep., 6, 37741. doi.org/10.1038/srep37741 
• Chieng, A., Wan, Z., Wang, S., 2024, Recent Advances in Real-Time Label-Free Detection of Small Molecules, Biosensors, 2024, 14 (2), 80. https://doi.org/10.3390/bios14020080 
• Dahlin, J. L., Walters, M. A., 2014, The essential roles of chemistry in high-throughput screening triage, Future Med. Chem., 6, 11, 1265-1290. doi.org/ 10.4155/fmc.14.60 
• Danishuddin, et al., 2025, Quantum intelligence in drug discovery: Advancing insights with quantum machine learning, Drug Discov Today, 30 (10), 104432. https://doi.org/10.1016/j.drudis.2025.104463 
• Das, D. et al., 2025, Recent Advances in Antibody Discovery Using Ultrahigh-Throughput Droplet Microfluidics: Challenges and Future Perspectives, Biosensors, 15 (7), 409. https://doi.org/10.3390/bios15070409 
• LabKey: What is High-Througput Screening? (2024). What is High-Throughput Screening (HTS)? | LabKey
• Leung, C. M. et al., 2022, A guide to the organ-on-a-chip, Nat Rew Methods Primers, 2, 33. https://doi.org/10.1038/s43586-022-00118-6 
• Ma, C. et al., 2021, Organ-on-a-Chip: A New Paradigm for Drug Development, Trends Pharmacol. Sci., 42, 2, 119-133. doi.org/10.1016/j.tips.2020.11.009
• Macarron, R. et al., 2011, Impact of high-throughput screening in biomedical research, Nat. Rev. Drug Discov., 10, 3, 188-195. doi.org/10.1038/nrd3368
• Mayr, L. M., Fuerst, P., 2008, The Future of High-Throughput Screening, J. Biomol. Screen., 443-448.
• Meissner, F. et al., 2022, The emerging role of mass spectrometry-based proteomics in drug discovery, Nat. Rev. Drug Discov., 21, 637-654. doi.org/10.1038/s41573-022-00409-3
• Seat, S., et al., 2024, A Decade in a Systematic Review: The Evolution and Impact of Cell Painting, bioRxiv. https://doi.org/10.1101/2024.05.04.592531 
• Smith, R. et al., 2025, Twenty-Five years of High-throughput Screening of Biological Samples with Mass Spectrometry: Current Platforms and Emerging Methods, ChemRxiv. https://doi.org/10.26434/chemrxiv-2025-db46t 
• Song, S-H., Jeong, S., 2024, State-of-the-art in high throughput organ-on-chip for biotechnology and pharmaceuticals, Clin Exp Reprod Med, 52 (2), 114-124. https://doi.org/10.5653/cerm.2024.06954 
• Subramani, C. et al., 2024, High content screening strategies for large-scale compound libraries with a focus on high-containment viruses, Antiviral Research, 221, 105764. https://doi.org/10.1016/j.antiviral.2023.105764 
• TheScientist: The Latest in Lab Automation (2023). The Latest in Lab Automation | The Scientist
• TheScientist: An Overview of High Throughput Screening (2024). An Overview of High Throughput Screening | The Scientist
• Van Goor, F. et al., 2009, Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770, Proc. Natl. Acad. Sci. U S A. 106 (44), 18825-18830. doi.org/10.1073/pnas.0904709106
• Vertex: FDA Approves KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis (2012). https://investors.vrtx.com/news-releases/news-release-details/fda-approves-kalydecotm-ivacaftor-first-medicine-treat 
• Wang, Y., Jeon, H. 2022, 3D cell cultures toward quantitative high-throughput drug screening, Trends Pharmacol. Sci., 43, 7, 569-581
• Winter, M. et al., 2023, Label-free high-throughput screening via acoustic ejection mass spectrometry put into practice, Slas Discov, 28 (5), 240-246. https://doi.org/10.1016/j.slasd.2023.04.001 
• Yang, Q. et al., 2025, Advanced droplet microfluidic platform for high-throughput screening of industrial fungi, Biosensors and Bioelectronics, 285, 117594. https://doi.org/10.1016/j.bios.2025.117594
• Zhang, J-H., Chung, T. D., Oldenburg, K. R., 1999, A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays, J Biomol Screen, 4 (2), 67-73. https://doi.org/10.1177/108705719900400206

Do you have an inquiry?

Get In Touch

Chemical libraries have become indispensable tools in modern research, particularly in the fields of chemical biology, pharmaceutical development, and materials science. At their core, a chemical library is a systematically organized collection of stored chemical compounds, most often small molecules, each annotated with essential information such as chemical structure, purity, quantity, and physicochemical characteristics. These libraries are designed to be screened rapidly against biological targets, typically through high-throughput screening (HTS), to identify bioactive molecules that can serve as starting points for drug discovery or as chemical probes for basic research.

The fundamental purpose of a chemical library is to maximize the exploration of chemical space. By sampling a diverse and extensive set of molecular entities, researchers significantly increase the probability of finding a “hit” compound—one that shows measurable activity against a given target or in a particular biological system. Greater diversity generally translates into higher hit rates, as the range of potential binding interactions with proteins, nucleic acids, or cellular pathways is expanded.

High-throughput screening is closely tied to the use of chemical libraries. HTS technologies allow tens of thousands, or even millions, of compounds to be tested rapidly against a defined target. This process accelerates lead identification, the critical first stage of transforming an initial hit into a lead compound with optimized activity and drug-like properties. Together, chemical libraries and HTS have become cornerstones of early-stage drug discovery, significantly reducing the time and resources required to progress from target identification to the generation of viable lead candidates.

Combinatorial chemical libraries are among the most widely recognized formats. They are created through combinatorial chemistry, a technique that systematically combines sets of chemical building blocks in all possible combinations. This approach generates vast collections of structurally diverse compounds that can cover large regions of chemical space.

Such libraries often include drug-like, lead-like, peptide-mimetic, or natural-product-like molecules, depending on the building blocks selected. Their strength lies in sheer scale and diversity, which makes them particularly useful for broad exploratory compound library screening campaigns in pharmaceutical pipelines.

DNA-encoded chemical libraries (DELs) represent a transformative technology in chemical library development. In a DEL, each small molecule is covalently linked to a unique DNA barcode that encodes its synthetic history and identity. This strategy enables the construction of libraries containing millions to billions of distinct compounds.

Screening DELs involves affinity selection, where the library is incubated with a biological target, followed by next-generation sequencing to identify bound molecules via their DNA tags. This approach allows ultra-high-throughput screening at a fraction of the cost of conventional HTS, since billions of compounds can be synthesized and interrogated in parallel with modest experimental infrastructure.

DELs have already yielded potent ligands for otherwise challenging targets, and several DEL-derived candidates have advanced into clinical trials. Their scalability and efficiency are redefining the scope of compound library screening.

In contrast to broadly diverse collections, targeted or focused chemical libraries are intentionally designed around specific protein families, receptor types, or therapeutic areas. Common targets include kinases, G protein-coupled receptors (GPCRs), proteases, and ion channels.

The creation of focused libraries often involves computational tools such as molecular docking (molecular) and virtual screening to pre-select scaffolds and functional groups most likely to interact with the chosen targets. Because the chemical space is intentionally constrained, these libraries frequently yield higher hit rates and produce cleaner structure–activity relationship (SAR) data, which simplifies subsequent optimization.

Fragment-based drug discovery relies on fragment libraries composed of very small molecules, typically with molecular weights below 300 Da. Although a fragment library may contain fewer than 5,000 compounds, these small molecules efficiently probe large regions of chemical space because of their low complexity.

Fragments generally bind weakly to targets, but their small size makes them excellent starting points for medicinal chemistry optimization. Reported hit rates for fragment screening are higher than those of conventional HTS, often ranging from 3–10%. Importantly, fragment-derived leads tend to have more favorable drug-like properties, including improved solubility, better ligand efficiency, and higher success rates during optimization.

Natural product libraries are derived from extracts of plants, fungi, marine organisms, or microorganisms. These libraries are particularly valued for their exceptionally high structural diversity and complexity, which arise from evolutionary pressure to interact with biological targets.

Compared with many synthetic libraries, natural products often occupy more drug-like chemical space and frequently demonstrate superior absorption, distribution, metabolism, excretion (ADME), and toxicity profiles. As a result, they often produce higher hit rates in compound libraries for drug discovery. However, working with natural product libraries presents challenges, including the need for additional purification and characterization of complex mixtures.

Several methods exist for the generation of chemical libraries, each offering distinct advantages:

• Combinatorial chemistry enables systematic exploration of large chemical spaces by assembling diverse building blocks.
• DNA-encoded synthesis integrates combinatorial chemistry with DNA barcoding to expand libraries to unprecedented scales.
• Natural product isolation brings evolutionary structural diversity into compound libraries, often yielding complex scaffolds inaccessible by synthetic methods.

The effectiveness of a compound library depends heavily on its design. Key design principles include:

• Chemical diversity: Incorporating a wide range of functional groups, ring systems, stereochemistry, and molecular sizes to maximize exploration of chemical space.
• Scaffold diversity: Ensuring a varied set of molecular frameworks to increase the likelihood of discovering novel binding modes.

Targeted physicochemical properties: For drug discovery, properties such as solubility, membrane permeability, and metabolic stability are prioritized to improve the likelihood of clinical success.

Computational chemistry plays a central role in the design and prioritization of compounds before synthesis.

• Virtual screening predicts the binding affinity of compounds in silico, allowing efficient triaging of candidates.
• Molecular docking provides insights into binding poses and molecular interactions with targets.
• Quantitative structure–activity relationship (QSAR) models identify structural features correlated with biological activity, guiding library optimization.

The long-term value of a chemical library depends on proper storage and handling. Key practices include:

• Temperature and environmental control: Maintaining stable, low-temperature conditions to prevent degradation.
• Labelling and coding: Robust barcoding and cataloguing systems to ensure accurate identification and retrieval.
• Routine quality control: Regular assessment of compound purity and activity to maintain screening reliability.

Digital platforms are critical for organizing and tracking chemical libraries. Databases capture chemical structures, physicochemical data, and screening results, ensuring accessibility and reproducibility. Integration with cloud-based systems allows annotation, collaboration, and secure sharing of information across research sites.

Automation and robotics technologies, including robotic storage and dispensing systems, are increasingly employed to manage the vast scale of modern compound libraries. Robotics improve efficiency, minimize human error, and enable rapid preparation of samples for HTS campaigns.

High-throughput screening remains the primary application of chemical libraries. Libraries are tested against defined molecular targets such as enzymes or receptors, or against whole-cell systems to assess phenotypic changes. Both approaches contribute to hit identification and subsequent lead optimization.

Phenotypic screening, in particular, has regained interest because it can reveal compounds that act through unexpected mechanisms, thereby uncovering new biology and therapeutic opportunities.

Fragment-based drug discovery contrasts with conventional HTS in both scale and methodology. Whereas HTS evaluates hundreds of thousands of compounds in large, diverse libraries, fragment screening interrogates smaller sets of very small molecules. Despite lower throughput, fragment screening often identifies higher-quality starting points, leading to drug candidates with improved physicochemical and pharmacokinetic properties.

• Cancer drug discovery: Chemical libraries have facilitated the development of kinase inhibitors, which transformed the treatment of cancers such as chronic myeloid leukemia and lung cancer.
• Antibiotic discovery: Natural product libraries have yielded new antibacterial scaffolds, crucial in combating rising antibiotic resistance.
• DNA-encoded libraries in oncology: DELs have uncovered ligands for difficult cancer targets, including protein–protein interactions previously considered undruggable.

Machine learning is increasingly integrated into chemical library development. Algorithms trained on large datasets can predict activity, optimize diversity, and prioritize compounds for synthesis and screening. This enhances efficiency, particularly for targeted or focused libraries.

The convergence of chemical and biological data sets is expanding opportunities for chemical library screening. Integration with genomics, transcriptomics, and proteomics enables the identification of ligands for previously intractable targets, including rare or context-specific proteins.

Emerging technologies such as microfluidic screening platforms are enabling ultra-high-throughput interrogation of libraries at reduced cost and sample volume. Automated storage and retrieval systems further streamline the handling of increasingly large compound collections.

Chemical libraries are a cornerstone of modern chemical and pharmaceutical research. From combinatorial chemical libraries and natural product collections to fragment libraries and DNA-encoded libraries, each approach contributes unique strengths to the collective effort of exploring chemical space. Advances in computational chemistry, automation, and machine learning continue to enhance the efficiency and effectiveness of chemical library development.

Through high-throughput screening and innovative screening technologies, chemical libraries enable the rapid identification of hits and leads, accelerating the path from target discovery to therapeutic development. As the field evolves, the integration of chemical libraries with biological and computational data promises to unlock new frontiers in drug discovery and beyond.

For researchers interested in learning more about our chemical libraries, DNA-encoded libraries (DELs), high-throughput screening technologies, or opportunities for collaboration, we encourage you to contact Vipergen. Our team is available to provide detailed information, discuss customized solutions, and explore potential research partnerships.

Do you have an inquiry?

Get In Touch

Hit identification (Hit ID) is the first decision gate in small-molecule discovery: finding chemical matter that measurably modulates a biological target or phenotype and is suitable for optimization. In practice, Hit ID narrows very large chemical collections to a small, structurally diverse set of “hits” that can be validated and evolved.

A hit is any compound with confirmed, reproducible activity and tractable chemistry; a lead goes further—meeting stricter thresholds for potency, selectivity, preliminary ADME/DMPK, and chemical developability that justify preclinical investment. The sections below outline the main methods to generate hits, how we validate them, and how Vipergen accelerates the path from hit to lead (Hughes 2011).

High-quality hit compounds are small molecules, peptides or biologics which suffice several criteria (Hughes 2011):

• Confirmed activity in the primary assay (and retested), with a concentration-response (typical hits are μM; exact thresholds are target/assay dependent).
• Selectivity: clean in counter-screens vs. close homologs/anti-targets; not a PAINS motif; non-aggregating; appropriate redox/fluorescence behavior.
• Tractability: synthetically accessible; clear points for analogue design; freedom-to-operate or IP novelty.
• Early ADME flags: solubility and stability compatible with follow-up assays; acceptable basic physicochemical properties.
• Verified identity & purity of the resynthesized material (off-DNA for DEL hits).

If all these criteria are not met, the compound must be characterized as a challenging hit. This can potentially make the hit-to-lead process and further steps of the drug discovery workflow more complex and ultimately failed projects.

Hit identification (HitID) comprises the screening strategy, assay design, data analysis, and triage used to move from millions/billions of candidates to a few dozen validated hits. Approaches include High-Throughput Screening (HTS), Virtual Screening (VS), DNA-Encoded Library (DEL) Screening, Fragment-Based Screening (FBS), and phenotypic screening, often combined in an integrated workflow tailored to the target class and data available (Ashraf 2024).

The central point in hit identification is the capability of screening large compound libraries against biological targets. Early identification of promising compounds helps prioritize research efforts which can streamline the development process. A successful hit identification campaign will lead to several structurally diverse compounds amenable for a hit-to-lead campaign, which will save time and resources further in the drug development phase. This will in turn also lead to better preclinical candidates. One would typically aim for multiple, diverse chemotypes to seed parallel hit-to-lead tracks.

Early-stage drug discovery can either start with a known ligand originating from academic literature, natural products or previous campaigns. Alternatively, de novo hit identification can be applied to identify novel chemical modulators. A range of different methods are employed for hit ID, which all focus on the screening of compound collections. Each method comes with strengths and weaknesses and below are the most promising methods summarized.

Practical rules for designing compounds most often follow Lipinski’s Rule of Five to keep in the oral drug-like space which is widely used physicochemical guidelines for both library design and during hit-to-lead to balance potency with permeability and exposure (Lipinski 1997). Alternatively, fragment bases drug discovery usually follows the Rule of Three to give low molecular weight and low lipophilicity with minimal H-bond features. This is done to maximize solubility and biophysical detectability in FBS.

Table 1: Commonly used design rules for oral bioavailability. The rule of 3 is used for fragment libraries.

Principle: assay large plated libraries (96/384/1536-well) with automated liquid handling and high-density readouts (luminescence, fluorescence, FRET/TR-FRET, absorbance, HTRF, Alpha).

Figure 2: High Throughput Screening workflow, which in short requires the assaying of hundreds of thousands of compounds in individual wells. Hits needs to be validated to sort out false positives.

High-Throughput screening (HTS) is a cornerstone in hit identification in drug discovery and has since the 1990s been the primary method for identifying potential hits. HTS involves testing large libraries of compounds against a biological target to identify those who exhibit activity. The process of HTS typically allows for a compound library (stored in multi-well plates) against a recombinantly expressed target protein or enzyme. Compounds showing the highest read-out such as fluorescence or luminescence can then quickly be identified, isolated and validated. 

However, HTS is often associated with high cost, as libraries needs to be acquired or synthesized and typically a robotic setup is utilized to handle the compound collection. Further, the compound collection has most often been synthesized in parallel which potentially hampers the diversity. False positives are also often identified from HTS which may arise from nonselective chemical reactions. Finally, either a biochemical or cellular assay, which generates a readout need to be developed. Where this is typically easy for common drug targets such as kinases and other enzymes, it can be more challenging for non-standard targets such as protein-protein interactions. 

Typical library size: hundreds of thousands to a few million individually plated compounds for primary HTS, depending on the collection and assay format.

Typical instrumentation: automated liquid handlers/dispensers; microplate readers; acoustic dispensers; plate washers; robotics and LIMS for data integrity.

Advantages:

• Direct measurement in a biochemical or cellular assay
• Mature automation; throughput to 104-106 test/day
• Broad assay menu; easy multiplexing

Limitations:

• Assay development burden (especially PPIs/membrane targets)
• Cost of library curation
• False positives (aggregation, autofluorescence, redox etc.)
• Library bias can limit chemical diversity

Principle: in silico triage of large chemical spaces using structure-based docking, ligand-based pharmacophores, QSAR/ML, or hybrids.
Representative tools: Glide, AutoDock Vina, GOLD, OpenEye FRED, MOE; ML-accelerated docking and AI pharmacophore modeling are increasingly used to shorten compute cycles.

Figure 3: Basic principle of Virtual Screening followed up by compound resynthesis and hit validation. 

With the exponentially growing capabilities of computational tools, in silico methods such as virtual screening has emerged as a powerful tool for hit ID. Virtual screening can be utilized to predict a small molecule interaction with a target protein before screening of physical compounds occurs. 

While it might seem appealing to screen a virtual library to reduce the number of compounds needed for physical screening, several challenges must be overcome to achieve high quality hit compounds. First of all, high-quality structural data is necessary for the target protein as this will be essential for the subsequent docking studies. For example, a low-resolution crystal structure could potentially yield false positives and a lot of wasted resources. 

Typical library size searched: millions→billions in silico (vendor + enumerated spaces), prior to wet-lab confirmation.

Typical instruments: docking (Glide, AutoDock Vina), pharmacophore/QSAR, ML accelerators for docking scoring.

Advantages:

• Cost-effective way to rank/cluster before wet screening
• Enables design-make-test-learn loops and scaffold hopping

Limitations:

• Dependent on target structure quality, protonation/tautomer states, and scoring functions
• Requires rigorous prospective validation and decoy testing

Principle: affinity selection of DNA-barcoded small molecules against a target; binders are identified by PCR/NGS counting and then resynthesized off-DNA for confirmation. Selections are quantified by NGS counts and gated against a mathematical background model; hits proceed to off-DNA resynthesis and IC₅₀/KD confirmation, followed by cellular EC₅₀/IC₅₀ and selectivity paneling (e.g., kinome maps) to prioritize series for SAR.

Figure 4: Basic overview of DNA Encoded Library Screening

DNA-Encoded Libraries (DELs) have emerged as powerful ways to generate compound collections ranging from a few millions to billions of compounds. Typically, a purified protein target is immobilized onto a solid support, which is then incubated with the DEL. Washing steps allow for the removal of non-binding library members and subsequent elution will isolate binding compounds which can be identified by PCR amplification followed by next generation sequencing (NGS). 

One challenge with DELs arises from the split-and-pool synthesis where the small molecule is synthesized at one end of the DNA strand and the encoding DNA is ligated at the other end. This allows for truncations to appear leading to a high rate of false positives of resynthesized hits. Vipergen utilizes the YoctoReactor® to synthesize libraries, which ensures that non-reacted building blocks fall out of the library during purification allowing for high fidelity of the library and a low false positives rate during screenings.1

Vipergen has developed binder trap enrichment (BTE) technology allowing us to screen without the need for immobilization of the target enzyme.2 Furthermore, Vipergen can now perform the screening in live cells using cellular binder trap enrichment (cBTE) overcoming the issue of expressing recombinant protein.3 This also allows for screening against proteins situated in membranes, which traditionally can be difficult to express recombinantly. 

Typical library size: millions to billions of DNA-encoded compounds can be screened in a single tube, leveraging NGS readout.

Typical instruments: Selection, NGS and off-DNA resynthesis. For Vipergen selections are run either using our BTE or cBTE platform. 

Advantages:

• Screens hundreds of millions of compounds rapidly
• Powerful for challenging targets and selectivity profiling

Vipergen advantages:

• YoctoReactor® synthesis delivers 100% code-to-compound fidelity by purifying after each step, minimizing truncates and improving hit validation rates.
• BTE® avoids target immobilization and counts ligand–target binding events in emulsion droplets—enabling residence-time-aware discovery and instant selectivity (multiplexed anti-targets).
• DELs-in-Cells (cBTE®) is the first and only method for screening DELs inside living cells, expanding target space and physiological relevance.

Figure 5: Schematic showing Vipergen’s cellular Binder Trap Enrichment in detail. Adapted from Petersen 2021.

Limitations: 

• Requires careful hit resynthesis and rigorous orthogonal validation
• Selection statistics and library design influence false negatives/positives
• Off-DNA translation essential before SAR

Principle: unbiased cell-based or organismal assays that measure phenotype (e.g., viability, morphology, reporter pathways) without prior target assignment. Can be part of a high throughput screening campaign.

Typical instruments: high-content imaging, transcriptomic profiling, CRISPR/ORF tools, proteomics.

Advantages:

• Finds first-in-class mechanisms and polypharmacology
• Captures cellular context (permeability, metabolism)

Limitations:

• Target deconvolution required (chemoproteomics, CRISPR perturb-seq, thermal proteome profiling)
• Assay noise/biology can complicate triage

Principle: screen low-MW fragments (≈150–250 Da) at higher concentrations to sample chemical space efficiently; merge/grow/link fragments into leads guided by structure.
Primary readouts / instrumentation: SPR (real-time binding), NMR (STD/WaterLOGSY), X-ray crystallography (soak/co-crystal), ITC (thermodynamics), DSF/nanoDSF (stability shifts), MST.

Figure 6: Basic workflow of Fragment Based Screening.

Fragment based screening (FBS) has emerged as an alternative tool to traditional HTS. By screening and identifying small chemical fragments, subsequent work can focus on linking several fragments together to more complex structures with high affinity. This technique called fragment merging can hereby take simple substructures and merge these to form high affinity compounds. Where the initial screening is usually easy, the subsequent merging can be a time-consuming challenge, which often relies on structural data of the target. 

Typical library size: 1–5K fragments (low-MW, high-solubility) screened with sensitive biophysical readouts.

Typical Instruments: SPR, ITC, DSF, NMR, MST, X-ray. 

Advantages:

• High hit rates; efficient exploration of binding pockets
• Structural methods provide clear design hypotheses

Limitations:

• Fragments are weak binders; requires sensitive biophysics and structure access
• Chemical merging/growing can be resource-intensive

• False positives/negatives: assay interference (autofluorescence, redox cyclers, aggregation), library artifacts, and truncates in poorly controlled DELs.
• Assay design risk: target construct/format, detection chemistry, and counter-screen choices profoundly influence outcomes.
• Compound/library quality: identity, purity, and diversity balance are critical to avoid fishing in a narrow chemical pond.
• Data analysis complexity: statistics, curve-fitting, and multi-condition selection analysis (e.g., selectivity panels) require robust pipelines.
• Translatability: bridging from biochemical hits to cellular engagement (permeability, efflux, metabolism).

How Vipergen helps: YoctoReactor® fidelity, BTE® residence-time awareness and multiplexed selectivity, and cBTE® in-cell screening directly address these pain points.

Even with robust libraries and high-quality assays, signal triage is critical: in our p38α campaign, >90% (22/24) of resynthesized DEL hits confirmed biochemically, yet potency rank did not strictly track read count—affinity, off-rate, and library member frequency each influence enrichment. This illustrates why orthogonal validation + early ADME are essential to convert “signal” into decision-ready chemical matter (Petersen 2016).

Hits identified from one of the above screening campaigns first needs to be validated. Compounds with apparent activity need to be isolated in high purity and tested in the primary assay. Here false positives arising from impurities (often seen in HTS), fluorescence or aggregation can be removed. Following this filtering of false positives, a range of secondary assays needs to be employed to show the desired biological activity. A typical set of assays which could be employed is the following:

• Flagging of Pan Assay Interference Compounds (PAINS), compounds with low solubility and compounds which have been observed as hits in prior screens.
• Counter screens against targets where the compounds should not be active and cytotoxicity assays.
• Orthogonal assays which serve to confirm target engagement. 

The range of assays which can be employed to validate a hit range from biophysical methods such as NMR and thermal shift assays to showing target engagement in cells. Ultimately, more disease relevant assays should be investigated to show a mode of action of the identified hit. Besides hits identified from the primary screening hits can be optimized through structure activity relationship (SAR) studies. 

Early ADME/Tox screens de-risk hits before scale-up: solubility and chemical stability in assay buffers; permeability/efflux flags for cellular assays; microsomal stability for clearance risk; and basic cytotoxicity or mechanism-agnostic counterscreens to catch liabilities. Combining orthogonal biophysics (SPR/ITC/DSF) with early ADME to separate true binders from assay artefacts and prioritize tractable chemotypes for SAR. Findings from our yR-DEL + BTE campaigns routinely move from biochemical potency to nanomolar cellular IC₅₀ with strong selectivity, minimizing false positives and accelerating H2L (Petersen 2016).

• SPR (surface plasmon resonance): Label-free, real-time kinetics (kon/koff), affinity, and stoichiometry
• ITC (isothermal titration calorimetry): Direct thermodynamics (ΔH, ΔS, Kd)
• DSF/nanoDSF (Differential Scanning Fluorimetry): Monitors protein stability shifts upon ligand binding for rapid triage
• NMR: Epitope mapping and weak-binder detection
• MSD (Meso Scale Discovery): Mobility changes reporting on binding

• IC50/EC50: Concentration producing 50% inhibition/effect in the assay; used to rank hits and monitor SAR
• Ki: Enzyme inhibition constant; model dependent but closer to mechanism than IC50
• KD: Equilibrium binding affinity from biophysics (e.g. SPR, ITC, or nanoDSF); useful across assay formats
• Z-factor: Assay quality statistics capturing separation and variability of positive/negative controls; used to qualify HTS readiness

Example from our DEL workflow: Resynthesis off-DNA hits proceeded from biochemical IC50 to cellular IC50 confirmation, including a 7 nM cellular IC50 p38α inhibitor discovery directly from a 12.6-million member yR library via BTE (Petersen 2016).

The goal of hit-to-lead (H2L) optimization is to convert validated hits into chemically coherent lead series with improved potency, selectivity, and developability. After initial confirmation and profiling, each hit undergoes systematic structure–activity relationship (SAR) exploration, physicochemical refinement, and biological evaluation to progress toward lead status.

A lead is a hit that meets clearly defined thresholds in several key areas:

• Potency: Demonstrates strong and reproducible activity, typically in the sub-micromolar range, with well-behaved concentration–response curves.
• Selectivity: Shows a clean profile in target family panels and key off-target assays, minimizing potential liabilities.
• ADME/DMPK properties: Exhibits suitable solubility, permeability, and metabolic stability, often supported by early in vitro or in vivo pharmacokinetic studies.
• Safety and chemical stability: Lacks reactive or toxicophoric groups and displays acceptable cytotoxicity and chemical stability.
• Synthetic tractability and IP position: Can be readily synthesized, modified, and protected, ensuring scalability and freedom-to-operate.

1. Hit reconfirmation and triage – resynthesis and purity verification, followed by confirmatory assays and orthogonal biophysical validation (e.g., SPR, ITC, DSF).
2. Initial SAR exploration – analogue synthesis guided by structural or ligand-based insights to map potency and selectivity trends.
3. Property optimization – adjust physicochemical and ADME parameters (solubility, lipophilicity, stability) to balance efficacy with developability.
4. Selectivity and safety profiling – expand counter-screening and secondary assays to identify clean, specific chemotypes.
5. Lead series selection – prioritize 1–3 promising series for detailed optimization and potential structural biology studies.

Vipergen’s DNA-encoded library (DEL) platforms—YoctoReactor®, BTE®, and cBTE®—streamline the hit-to-lead transition by delivering high-quality, well-validated hits with immediate structural diversity. These platforms reduce false positives, enable residence-time-aware and cellularly relevant hit validation, and shorten the path to robust, patentable lead candidates (Petersen 2021).

Through close collaboration, Vipergen supports partners from initial hit validation through SAR expansion and lead optimization, ensuring that each project advances with efficiency, selectivity, and scientific confidence.

• AI/ML-accelerated screening: ML models that pre-score docking or learn from prior campaigns to triage libraries faster; AI pharmacophore modeling complements structure-based methods (Singh 2024, Hayek-Orduz 2025).
• In-cell selection & target engagement: technologies like cBTE® extend discovery inside living cells, improving physiological relevance (Petersen 2021).
• Next-gen assays: high-content phenotypic imaging, microfluidics, and multiplexed biochemical/cell panels to increase information per screen.
• Integrated workflows: combining VS → DEL/HTS → biophysics/phenotypic back-validation to exploit orthogonal strengths (Ashraf 2024).

• YoctoReactor® DELs: 100% code–compound match by design → cleaner data, fewer truncates, higher hit validation rates.
• BTE® (in vitro): no immobilization, residence-time-aware selections, instant selectivity vs. anti-targets with μg protein consumption.
• cBTE® (in living cells): first and only DEL screening inside living cells—broadens target scope and improves translational relevance.
• Selectivity Direct & partner network: multiplexed target/anti-target screening and structure support to accelerate SAR.
• Engagement models from fee-for-service to integrated collaborations; Express and Snap options for turnaround and budget flexibility.

Explore our In vitro and In living cell Hit Identification Services or get in touch via Inquiry.

• Ashraf, S. N. et. al., Hit me with your best shot: Integrated hit discovery for the next generation of drug targets, Drug Discov Today, 29 (10), 104143 (2024). https://doi.org/10.1016/j.drudis.2024.104143 
• Ghose, A. K. et. al. A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. 1. A Qualitative and Quantitative Characterization of Known Drug Databases, J Comb Chem, 1 (1), 55-68 (1999). https://doi.org/10.1021/cc9800071 
• Hayek-Orduz, Y. et. al. dyphAI dynamic pharmacophore modeling with AI: a tool for efficient screening of new acetylcholinesterase inhibitors, Front Chem, 13, 1479763 (2025). https://doi.org/10.3389/fchem.2025.1479763 
• Hughes, J. P. et. al., Principles of early drug discovery, Br J Pharmacol, 162 (6), 1239-1249 (2011). https://doi.org/10.1111/j.1476-5381.2010.01127.x
• Lipinski, C. A. et. al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv Drug Deliv Rev, 23 (1-3), 3-25 (1997). https://doi.org/10.1016/S0169-409X(96)00423-1 
• Petersen, L. K. et. al. Novel p38α MAP kinase inhibitors identified from yoctoReactor DNA-encoded small molecule library, MedChemComm, 7, 1332-1339 (2016). https://doi.org/10.1039/C6MD00241B  
• Petersen, L. K. et. al. Screening of DNA-Encoded Small Molecule Libraries inside a Living Cell, J Am Chem Soc, 143 (7), 2751-2756 (2021). https://doi.org/10.1021/jacs.0c09213 
• Singh, S. et. al., Advances in Artificial Intelligence (AI)-assisted approaches in drug screening, Artif Intell Chem, 2 (1), 100039 (2024). https://doi.org/10.1016/j.aichem.2023.100039
• Veber, D. F. et. al., Molecular Properties That Influence the Oral Bioavailability of Drug Candidates, J Med Chem, 45 (12), 2615-2623 (2002). https://doi.org/10.1021/jm020017n

Do you have an inquiry?

Get In Touch